Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin F Bachmann

Showing results (231-240 of 250) with videos related to

Pageof 25
Sort By:
Vaccines|August 29, 2024
Preclinical Evaluation of Novel Sterically Optimized VLP-Based Vaccines against All Four DENV SerotypesDominik A Rothen, Sudip Kumar Dutta, Pascal S Krenger, et al.
Vaccines|May 5, 2017
Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivaxGustavo Cabral-Miranda, Matthew D Heath, Mona O Mohsen, et al.
Viruses|March 12, 2020
Immunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of OwnersFranziska Thoms, Stefanie Haas, Aline Erhart, et al.
Vaccines|September 28, 2024
Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle VaccinesDominik A Rothen, Sudip Kumar Dutta, Pascal S Krenger, et al.
Frontiers in Immunology|June 4, 2019
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-VaccineMona O Mohsen, Monique Vogel, Carsten Riether, et al.
Diseases (Basel, Switzerland)|November 25, 2018
DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based VaccinesGustavo Cabral-Miranda, Ahmed M Salman, Mona O Mohsen, et al.
Allergy|April 11, 2022
Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concernDominik A Rothen, Pascal S Krenger, Aleksandra Nonic, et al.
Journal of Hypertension|December 5, 2006
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityPatrice M Ambühl, Alain C Tissot, Alma Fulurija, et al.
Immunity|March 29, 2022
Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sitesAndrew J MacLean, Niamh Richmond, Lada Koneva, et al.
The Journal of Allergy and Clinical Immunology|December 24, 2019
Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergensFederico Storni, Andris Zeltins, Ina Balke, et al.
Pageof 25

Showing results (231-240 of 250) with videos related to

Sort By:
Pageof 25
Vaccines|August 29, 2024
Preclinical Evaluation of Novel Sterically Optimized VLP-Based Vaccines against All Four DENV SerotypesDominik A Rothen, Sudip Kumar Dutta, Pascal S Krenger, et al.
Vaccines|May 5, 2017
Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivaxGustavo Cabral-Miranda, Matthew D Heath, Mona O Mohsen, et al.
Viruses|March 12, 2020
Immunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of OwnersFranziska Thoms, Stefanie Haas, Aline Erhart, et al.
Vaccines|September 28, 2024
Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle VaccinesDominik A Rothen, Sudip Kumar Dutta, Pascal S Krenger, et al.
Frontiers in Immunology|June 4, 2019
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-VaccineMona O Mohsen, Monique Vogel, Carsten Riether, et al.
Diseases (Basel, Switzerland)|November 25, 2018
DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based VaccinesGustavo Cabral-Miranda, Ahmed M Salman, Mona O Mohsen, et al.
Allergy|April 11, 2022
Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concernDominik A Rothen, Pascal S Krenger, Aleksandra Nonic, et al.
Journal of Hypertension|December 5, 2006
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityPatrice M Ambühl, Alain C Tissot, Alma Fulurija, et al.
Immunity|March 29, 2022
Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sitesAndrew J MacLean, Niamh Richmond, Lada Koneva, et al.
The Journal of Allergy and Clinical Immunology|December 24, 2019
Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergensFederico Storni, Andris Zeltins, Ina Balke, et al.
Pageof 25